Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

COPD (Chronic Obstructive Pulmonary Disease) Clinical Trials

A listing of COPD (Chronic Obstructive Pulmonary Disease) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (311) clinical trials

You must be 40 years of age or older You must have a diagnosis of COPD for at least a year You must currently be treating your COPD with a daily medication for at least 8 weeks prior to starting the study You must be a current or former smoker ...

Phase N/A

This study will be testing an investigational medication for COPD Eligibility Criteria: -Age 40 years or older -Diagnosis of COPD for at least 12 months -Current Smoker or Ex-Smoker -Other criteria may apply Other Details: Qualified volunteers will receive study medication, study supplies and any study required testing at no ...

Phase

We are looking for individuals to participate in a research study to determine the safety and efficacy of an investigational medication. Eligibility Criteria: If you are: - 40 years of age or older - are a previous or current smoker - have a diagnosis of chronic obstructive pulmonary disease (COPD) ...

Phase N/A

Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging

In this study the efficacy of Roflumilast in addition to LAMA/LABA therapy will be assessed using Functional Respiratory Imaging. In total 40 Chronic obstructive pulmonary disease (COPD) patients, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages C and D, who are stable on LABA/LAMA therapy and who are prone ...

Phase

Pilot Study of Physiological Effect of High-Flow Nasal Cannula on Respiratory Pattern and Work of Breathing

HFNC has been shown to have many advantages in the treatment of acutely hypoxemic patients, improving their clinical outcome. The exact mechanism underlying this beneficial effect is still not completely understood. Few studies have analyzed the effect of HFNC on ventilatory pattern and work of breathing. The majority of these ...

Phase N/A

Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort

This study will investigate whether switching symptomatic COPD patients from a fixed-dose combination of salmeterol/fluticasone 50/500 g b.i.d. to a fixed dose combination of QVA149 110/50 g o.d. leads to improved lung function and airflow. It will also assess the effect on symptom burden, breathlessness, and use of rescue medication ...

Phase

A Study to Evaluate the Safety Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation

The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum in patients experiencing an exacerbation of COPD, with or without treatment with GSK2269557. The efficacy of treatment with ...

Phase

Seasonal Influenza Vaccine Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease

Primary Objectives: To evaluate the magnitude of the humoral immune responses to quadrivalent vs trivalent influenza vaccines in adults between the age of 50 and 64 years with a prior diagnosis of GOLD Stage C and D COPD (vs. those patients without COPD). To demonstrate immunogenicity by measuring hemagglutination inhibiting ...

Phase

A Randomized Multicenter Open-label Parallel-group 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

To demonstrate superiority of QVA149 (110/50 g) once daily compared to tiotropium 18 g once daily in terms of trough forced expiratory volume in 1 second (FEV1) (mean of 45 min and 15 min pre-dose) following 12 weeks of treatment in mild to moderate symptomatic COPD patients

Phase

Ultibro Versus Spiriva Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD

The foundation of COPD therapy is to combine inhaled therapy to optimize benefits as it was done several years ago by associating short-acting 2-agonists and muscarinic antagonist. The recent availability of once-daily LABA/LAMA fixed combination products makes this therapeutic strategy even more appealing and appears as a promising treatment option ...

Phase